However, the optimal strategy after progression remains uncertain.<h4>Methods</h4>PubMed, Cochrane, and Embase databases were searched in April 2025 for phase II/III clinical trials evaluating CDK4/6i rechallenge in advanced breast cancer. This evidence concerns the gene CDK4 and breast cancer.